Skip to main content
SpringerLink
Log in

Potential value of genomic testing in early breast cancer

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Dinan MA, et al. Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011. Journal of the National Comprehensive Cancer Network : 11 Mar 2019. Available from: URL: https://doi.org/10.6004/jnccn.2018.7097

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Potential value of genomic testing in early breast cancer. PharmacoEcon Outcomes News 826, 21 (2019). https://doi.org/10.1007/s40274-019-5823-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-5823-8

Search

Navigation